Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed .
作者信息
Noguchi Yoshihiro, Yan Miao, Tachi Tomoya, Yoshimura Tomoaki
机构信息
Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Gifu, Japan
Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
出版信息
J Immunother Cancer. 2024 Apr 22;12(4):e009137. doi: 10.1136/jitc-2024-009137.
Abstract
摘要
相似文献
1
Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed .
J Immunother Cancer. 2024 Apr 22;12(4):e009137. doi: 10.1136/jitc-2024-009137.
2
Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi .
J Immunother Cancer. 2024 Apr 22;12(4):e009300. doi: 10.1136/jitc-2024-009300.
3
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.
Cancer. 2025 Feb 1;131(3):e35738. doi: 10.1002/cncr.35738.
4
Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Leukemia. 2017 Apr;31(4):777-787. doi: 10.1038/leu.2016.391. Epub 2016 Dec 28.
5
Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.
J Clin Oncol. 2016 Apr 1;34(10):1131-3. doi: 10.1200/JCO.2015.64.9970. Epub 2016 Feb 16.
6
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
Circ Res. 2021 May 28;128(11):1780-1801. doi: 10.1161/CIRCRESAHA.120.315894. Epub 2021 May 3.
7
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16.
8
Perils and Problems in Bispecific T-Cell Engager Antibodies.
Curr Drug Saf. 2024 Feb 27. doi: 10.2174/0115748863286774240219094217.
9
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.
Leukemia. 2018 May;32(5):1239-1243. doi: 10.1038/s41375-018-0014-3. Epub 2018 Jan 31.
10
[The Chinese clinical expert consensus for the BCMA bispecific T cell engager in the treatment of multiple myeloma (2025)].
Zhonghua Xue Ye Xue Za Zhi. 2025 Mar 14;46(3):209-215. doi: 10.3760/cma.j.cn121090-20250202-00050.
本文引用的文献
1
Detection Algorithms for Simple Two-Group Comparisons Using Spontaneous Reporting Systems.
Drug Saf. 2024 Jun;47(6):535-543. doi: 10.1007/s40264-024-01404-w. Epub 2024 Feb 22.
2
Cardiovascular toxicities associated with bispecific T-cell engager therapy.
J Immunother Cancer. 2024 Feb 21;12(2):e008518. doi: 10.1136/jitc-2023-008518.
3
Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source.
Brief Bioinform. 2021 Nov 5;22(6). doi: 10.1093/bib/bbab347.
Zotero 插件